Ionolyte (Magnesium Chloride Hexahydrate, Potassium Chloride, Sodium Chloride, Sodium Acetate Trihydrate)

Magnesium chloride hexahydrate dissociates in the bloodstream to release magnesium ions, which are essential for enzymatic reactions, nerve conduction and muscle function. Together with potassium, sodium and acetate, the solution expands extracellular fluid volume and corrects specific electrolyte deficits, while acetate is metabolized to bicarbonate to aid in correcting metabolic acidosis.

The dose of Ionolyte is individualized by the prescribing clinician based on the patient’s electrolyte profile, fluid status and clinical condition. Healthcare professionals calculate the appropriate volume and infusion rate to safely correct the identified deficits, following institutional protocols and monitoring guidelines.

The safety of Ionolyte in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and treatment decisions should be made by the prescriber in consultation with obstetric specialists.

To order Ionolyte, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Ionolyte provides a balanced combination of magnesium, potassium, sodium and acetate, whereas many standard electrolyte solutions contain only sodium and chloride. The inclusion of magnesium and acetate makes Ionolyte particularly useful for correcting hypomagnesemia and metabolic acidosis, offering a broader electrolyte replacement profile compared with simpler saline‑based fluids.

Ionolyte should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vials in their original packaging until use, and inspect for any particulate matter or discoloration before administration.

Ionolyte is administered intravenously as a sterile solution for injection. It is typically infused through a controlled infusion set, with the rate determined by the prescriber based on the patient’s electrolyte deficits and clinical status. Infusion should be monitored for signs of electrolyte imbalance or adverse reactions.

Serious risks include severe hypermagnesemia, hyperkalemia or hypernatremia, which can lead to cardiac arrhythmias, respiratory depression or cardiac arrest. Anaphylactic reactions and metabolic alkalosis from excessive acetate conversion are also possible. Continuous monitoring of electrolyte levels and cardiac function is essential during therapy.

Ionolyte should be avoided in patients with known hypersensitivity to any of its components, in those with severe renal impairment where electrolyte clearance is markedly reduced, and in individuals with untreated hypermagnesemia, hyperkalemia or hypernatremia. Clinical judgment is required for patients with unstable cardiac conditions.